Systems and methods for directly interacting with communications module of wound therapy apparatus

Information

  • Patent Grant
  • 12083262
  • Patent Number
    12,083,262
  • Date Filed
    Tuesday, June 13, 2023
    a year ago
  • Date Issued
    Tuesday, September 10, 2024
    2 months ago
Abstract
Embodiments of negative pressure wound therapy systems and methods are disclosed. In some embodiments, a wound therapy system includes a negative pressure source configured to provide negative pressure via a fluid flow path to a wound dressing, a first circuit board assembly including a first controller configured to control a wound therapy with the wound dressing by activation and deactivation of the negative pressure source, and a second circuit board assembly in communication with the first circuit board assembly, the second circuit board assembly separate from the first circuit board assembly. The second circuit board assembly can include a second controller configured to wirelessly communicate therapy data via a communication network, receive an executable command from an electronic device, and execute the executable command without providing the executable command to the first controller.
Description
BACKGROUND

Embodiments of the present disclosure relate to methods and apparatuses for dressing and treating a wound with negative or reduced pressure therapy or topical negative pressure (TNP) therapy. In particular, but without limitation, embodiments disclosed herein relate to negative pressure therapy devices, methods for controlling the operation of TNP systems, and methods of using TNP systems.


SUMMARY

In some embodiments, an apparatus for applying negative pressure to a wound is disclosed. The apparatus can include a housing, a pressure source, a first circuit board assembly, and a second circuit board assembly. The pressure source can be at least partially enclosed by the housing and provide negative pressure via a fluid flow path to a wound dressing. The first circuit board assembly can be at least partially enclosed by the housing and include a first controller configured to control a wound therapy with the wound dressing by activation and deactivation of the pressure source. The second circuit board assembly can be at least partially enclosed by the housing and in communication with the first circuit board assembly. The second circuit board assembly can be separate from the first circuit board assembly and include a second controller. The second controller can: communicate therapy data via a communication network, the therapy data being indicative of a characteristic of the wound therapy, receive an executable command from an electronic device, and execute the executable command without providing the executable command to the first controller.


The apparatus of the preceding paragraph can include one or more of the following features: The second controller can receive the executable command from the electronic device via a serial bus electrically connecting the second circuit board assembly and the electronic device. The second controller can receive the executable command from the electronic device via wireless communication. The second controller can wirelessly communicate the therapy data via the communication network. The electronic device may not be supported by the housing. The second controller can receive and execute the executable command without the wound therapy being interrupted. The second controller can receive and execute the executable command to test an operation of the second controller. The second controller can receive and execute the executable command despite the first controller not being operational. The executable command can be a request for hardware or software version data, and execution of the executable command by the second controller can cause the second controller to transmit the hardware or software version data to the electronic device. Execution of the executable command by the second controller can cause the second controller to change a setting associated with operation of the second controller. Execution of the executable command by the second controller can cause the second controller to communicate the therapy data via another communication network rather than the communication network. Execution of the executable command by the second controller can cause the second controller to perform an operation associated with the communication network. The executable command can be an attention (AT) command. The executable command can be a command of a Hayes command set. The second circuit board assembly can include a modem that includes the second controller. The apparatus can further include a third circuit board assembly including a connector interface, and the first hardware controller can receive another executable command via the connector interface from the electronic device. The second hardware controller can receive another executable command from the first hardware controller. The second hardware controller can enter (i) a data mode in which the data processed by the second hardware controller is not executed and (ii) a command mode in which data processed by the second hardware controller is executed. The first controller can gather the therapy data and provide the therapy data to the second controller for transmission. The second controller can receive another executable command from the electronic device and provide the another executable command to the first controller for execution.


In some embodiments, a method is disclosed for operating a wound therapy device that includes a first circuit board assembly and a second circuit board assembly separate from the first circuit board assembly. The method can include, by a first controller mounted to the first circuit board assembly, controlling application of negative pressure with a pressure source to a wound dressing. In addition, the method can include by a second controller mounted to the second circuit board assembly: communicating therapy data via a communication network, the therapy data being indicative of a characteristic of wound therapy performed with the pressure source, receiving an executable command from an electronic device, and executing the executable command without processing the executable command with the first controller.


The method of the preceding paragraph can include one or more of the following features; The receiving can include receiving the executable command from the electronic device via a serial bus electrically connecting the second circuit board assembly and the electronic device. The receiving can include receiving the executable command from the electronic device via wireless communication. The communicating can include wirelessly communicating the therapy data via the communication network. The receiving and executing can include receiving and executing the executable command without the wound therapy being interrupted. The executing can include executing the executable command to test an operation of the second controller. The receiving and executing can include receiving and executing the executable command despite the first controller not being operational. The executable command can be a request for hardware or software version data, and the executing can cause the second controller to transmit the hardware or software version data to the electronic device. The executing can cause the second controller to change a setting associated with operation of the second controller. The executing can cause the second controller to communicate the therapy data via another communication network rather than the communication network.





BRIEF DESCRIPTION OF THE DRAWINGS

Features and advantages of the present disclosure will be apparent from the following detailed description, taken in conjunction with the accompanying drawings of which:



FIG. 1 illustrates a reduced pressure wound therapy system according to some embodiments.



FIGS. 2A, 2B, and 20 illustrate a pump assembly and canister according to some embodiments.



FIG. 3A illustrates an electrical component schematic of a pump assembly according to some embodiments.



FIG. 3B illustrates communication with the pump assembly of FIG. 3A according to some embodiments.



FIGS. 4A, 4B, 4C, 40, 4E, and 4F illustrate a pump assembly according to some embodiments.



FIGS. 5A, 5B, 5C, 5D, and 5E illustrate a pump assembly according to some embodiments.



FIGS. 6A and 6B illustrate a front and back of a main circuit board assembly according to some embodiments.



FIGS. 7A and 7B illustrate a communications circuit board assembly according to some embodiments.



FIGS. 8A and 8B illustrate communications interfaces of a pump assembly according to some embodiments,



FIGS. 9A and 9B illustrate another pump assembly according to some embodiments.



FIG. 10 illustrates yet another pump assembly according to some embodiments.



FIG. 11 illustrates a process performable by a pump assembly according to some embodiments.





DETAILED DESCRIPTION

The present disclosure relates to methods and apparatuses for dressing and treating a wound with reduced pressure therapy or topical negative pressure (TNP) therapy. In particular, but without limitation, embodiments of this disclosure relate to negative pressure therapy apparatuses, methods for controlling the operation of TNP systems, and methods of using TNP systems. The methods and apparatuses can incorporate or implement any combination of the features described below.


Many different types of wound dressings are known for aiding in the healing process of a human or animal. These different types of wound dressings include many different types of materials and layers, for example, gauze, pads, foam pads or multi-layer wound dressings. TNP therapy, sometimes referred to as vacuum assisted closure, negative pressure wound therapy, or reduced pressure wound therapy, can be a beneficial mechanism for improving the healing rate of a wound. Such therapy is applicable to a broad range of wounds such as incisional wounds, open wounds and abdominal wounds or the like.


TNP therapy can assist in the closure and healing of wounds by reducing tissue oedema, encouraging blood flow, stimulating the formation of granulation tissue, removing excess exudates, and reducing bacterial load and thus, infection to the wound. Furthermore, TNP therapy can permit less outside disturbance of the wound and promote more rapid healing.


As is used herein, reduced or negative pressure levels, such as −X mmHg, represent pressure levels that are below atmospheric pressure, which typically corresponds to 760 mmHg (or 1 atm, 29.93 inHg, 101,325 kPa, 14.696 psi, etc.). Accordingly, a negative pressure value of −X mmHg reflects pressure that is X mmHg below atmospheric pressure, such as a pressure of (760−X) mmHg. In addition, negative pressure that is “less” or “smaller” than −X mmHg corresponds to pressure that is closer to atmospheric pressure (for example, −40 mmHg is less than −60 mmHg). Negative pressure that is “more” or “greater” than −X mmHg corresponds to pressure that is further from atmospheric pressure (for example, −80 mmHg is more than −60 mmHg).


INTRODUCTION

A pump assembly of a TNP system can include multiple controllers or processors used to control the various operations of the pump assembly. A main controller can, for example, be used to orchestrate an overall functioning of the pump assembly, and one or more other controllers can be used to control one or more specialized functions of the pump assembly (such as communications, negative pressure control, or user interface operations) under direction from the main controller.


A pump assembly can communicate with an electronic device that is separate from the pump assembly by having a main controller of the pump assembly exchange messages with the electronic device. The electronic device may, for instance, transmit an executable command as part of a message to the main controller. The main controller can then receive and process the message and execute the executable command or pass along the executable command for execution by one or more other controllers of the pump assembly.


If a main controller of a pump assembly is the sole channel through which an electronic device can communicate particular information between the electronic device and one or more other controllers of the pump assembly, this can be undesirable in certain instances because the main controller can introduce delay, control limits, or errors to the communication between the electronic device and the one or more other controllers. In certain instances, the main controller may devote resources to communicating with the electronic device, which may negatively affect (for example, delay or interrupt) provision of negative pressure wound therapy.


The pump assemblies as described herein can overcome such challenges, in certain embodiments, by enabling communication between the electronic device and the one or more other controllers without relying on the main controller to serve as an intermediary for the communication. The lack of the intermediary moreover can be particularly advantageous, in certain embodiments, when device testing and troubleshooting at least because testing and troubleshooting can be made easier and faster through direct rather than indirect communication.


In some embodiments, a pump assembly can include a communications controller (for instance, a wireless/GPS controller) that may directly communicate with an electronic device without a main controller of the pump assembly functioning as an arbiter between the electronic device and the communications controller. The communications between the electronic device and the communications controller can be via wired communication (for instance, Universal Serial Bus (USB) communication) or wireless communication. The electronic device can send executable commands, such as attention (AT) commands, to the communications controller for execution by the communications controller. One executable command can, for example, cause the communications controller to transition from operating on one network to operating on a different network, such as from a cellular network operated by one provider to a different cellular network operated by a different provider. Moreover, the electronic device can communicate about or change settings of the communications controller without affecting (for example, interrupting) therapy being performed by the pump assembly under control of the main controller.


System Overview



FIG. 1 illustrates an embodiment of a negative or reduced pressure wound treatment (or TNP) system 100 comprising a wound filler 130 placed inside a wound cavity 110, the wound cavity sealed by a wound cover 120. The wound filler 130 in combination with the wound cover 120 can be referred to as wound dressing. A single or multi lumen tube or conduit 140 is connected the wound cover 120 with a pump assembly 150 configured to supply reduced pressure. The wound cover 120 can be in fluidic communication with the wound cavity 110. In any of the system embodiments disclosed herein, as in the embodiment illustrated in FIG. 1, the pump assembly can be a canisterless pump assembly (meaning that exudate is collected in the wound dressing or is transferred via tube 140 for collection to another location). However, any of the pump assembly embodiments disclosed herein can be configured to include or support a canister. Additionally, in any of the system embodiments disclosed herein, any of the pump assembly embodiments can be mounted to or supported by the dressing, or adjacent to the dressing.


The wound filler 130 can be any suitable type, such as hydrophilic or hydrophobic foam, gauze, inflatable bag, and so on. The wound filler 130 can be conformable to the wound cavity 110 such that it substantially fills the cavity. The wound cover 120 can provide a substantially fluid impermeable seal over the wound cavity 110. The wound cover 120 can have a top side and a bottom side, and the bottom side adhesively (or in any other suitable manner) seals with wound cavity 110. The conduit 140 or lumen or any other conduit or lumen disclosed herein can be formed from polyurethane, PVC, nylon, polyethylene, silicone, or any other suitable material.


Some embodiments of the wound cover 120 can have a port (not shown) configured to receive an end of the conduit 140. For example, the port can be Renays Soft Port available from Smith & Nephew. In other embodiments, the conduit 140 can otherwise pass through or under the wound cover 120 to supply reduced pressure to the wound cavity 110 so as to maintain a desired level of reduced pressure in the wound cavity. The conduit 140 can be any suitable article configured to provide at least a substantially sealed fluid flow pathway between the pump assembly 150 and the wound cover 120, so as to supply the reduced pressure provided by the pump assembly 150 to wound cavity 110.


The wound cover 120 and the wound filler 130 can be provided as a single article or an integrated single unit. In some embodiments, no wound filler is provided and the wound cover by itself may be considered the wound dressing. The wound dressing may then be connected, via the conduit 140, to a source of negative pressure, such as the pump assembly 150. The pump assembly 150 can be miniaturized and portable, although larger conventional pumps such can also be used.


The wound cover 120 can be located over a wound site to be treated. The wound cover 120 can form a substantially sealed cavity or enclosure over the wound site. In some embodiments, the wound cover 120 can be configured to have a film having a high water vapor permeability to enable the evaporation of surplus fluid, and can have a superabsorbing material contained therein to safely absorb wound exudate. It will be appreciated that throughout this specification reference is made to a wound. In this sense it is to be understood that the term wound is to be broadly construed and encompasses open and closed wounds in which skin is torn, cut or punctured or where trauma causes a contusion, or any other surficial or other conditions or imperfections on the skin of a patient or otherwise that benefit from reduced pressure treatment. A wound is thus broadly defined as any damaged region of tissue where fluid may or may not be produced. Examples of such wounds include, but are not limited to, acute wounds, chronic wounds, surgical incisions and other incisions, subacute and dehisced wounds, traumatic wounds, flaps and skin grafts, lacerations, abrasions, contusions, burns, diabetic ulcers, pressure ulcers, stoma, surgical wounds, trauma and venous ulcers or the like. The components of the TNP system described herein can be particularly suited for incisional wounds that exude a small amount of wound exudate.


Some embodiments of the system are designed to operate without the use of an exudate canister. Some embodiments can be configured to support an exudate canister. In some embodiments, configuring the pump assembly 150 and tubing 140 so that the tubing 140 can be quickly and easily removed from the pump assembly 150 can facilitate or improve the process of dressing or pump changes, if necessary. Any of the pump embodiments disclosed herein can be configured to have any suitable connection between the tubing and the pump.


The pump assembly 150 can be configured to deliver negative pressure of approximately −80 mmHg, or between about −20 mmHg and 200 mmHg in some implementations. Note that these pressures are relative to normal ambient atmospheric pressure thus, −200 mmHg would be about 560 mmHg in practical terms. The pressure range can be between about −40 mmHg and −150 mmHg. Alternatively a pressure range of up to −75 mmHg, up to −80 mmHg or over −80 mmHg can be used. Also a pressure range of below −75 mmHg can be used. Alternatively a pressure range of over approximately −100 mmHg, or even 150 mmHg, can be supplied by the pump assembly 150.


In operation, the wound filler 130 is inserted into the wound cavity 110 and wound cover 120 is placed so as to seal the wound cavity 110, The pump assembly 150 provides a source of a negative pressure to the wound cover 120, which is transmitted to the wound cavity 110 via the wound filler 130. Fluid (e.g., wound exudate) is drawn through the conduit 140, and can be stored in a canister. In some embodiments, fluid is absorbed by the wound filler 130 or one or more absorbent layers (not shown).


Wound dressings that may be utilized with the pump assembly and other embodiments of the present application include Renasys-F, Renasys-G, Renasys AB, and Pico Dressings available from Smith & Nephew. Further description of such wound dressings and other components of a negative pressure wound therapy system that may be used with the pump assembly and other embodiments of the present application are found in U.S. Patent Publication Nos. 2011/0213287, 2011/0282309, 2012/0116334, 2012/0136325, and 2013/0110058, which are incorporated by reference in their entirety. In other embodiments, other suitable wound dressings can be utilized.



FIG. 2A illustrates a front view of a pump assembly 230 and canister 220 according to some embodiments. As is illustrated, the pump assembly 230 and the canister are connected, thereby forming a negative pressure wound therapy device. The pump assembly 230 can be similar to or the same as the pump assembly 150 in some embodiments.


The pump assembly 230 includes one or more indicators, such as visual indicator 202 configured to indicate alarms and visual indicator 204 configured to indicate status of the TNP system. The indicators 202 and 204 can be configured to alert a user, such as patient or medical care provider, to a variety of operating or failure conditions of the system, including alerting the user to normal or proper operating conditions, pump failure, power supplied to the pump or power failure, detection of a leak within the wound cover or flow pathway, suction blockage, or any other similar or suitable conditions or combinations thereof. The pump assembly 230 can comprise additional indicators. The pump assembly can use a single indicator or multiple indicators. Any suitable indicator can be used such as visual, audio, tactile indicator, and so on. The indicator 202 can be configured to signal alarm conditions, such as canister full, power low, conduit 140 disconnected, seal broken in the wound seal 120, and so on. The indicator 202 can be configured to display red flashing light to draw user's attention. The indicator 204 can be configured to signal status of the TNP system, such as therapy delivery is ok, leak detected, and so on. The indicator 204 can be configured to display one or more different colors of light, such as green, yellow, etc. For example, green light can be emitted when the TNP system is operating properly and yellow light can be emitted to indicate a warning.


The pump assembly 230 includes a display or screen 206 mounted in a recess 208 formed in a case of the pump assembly. The display 206 can be a touch screen display. The display 206 can support playback of audiovisual (AV) content, such as instructional videos. As explained below, the display 206 can be configured to render a number of screens or graphical user interfaces (GUIs) for configuring, controlling, and monitoring the operation of the TNP system. The pump assembly 230 comprises a gripping portion 210 formed in the case of the pump assembly. The gripping portion 210 can be configured to assist the user to hold the pump assembly 230, such as during removal of the canister 220. The canister 220 can be replaced with another canister, such as when the canister 220 has been filled with fluid.


The pump assembly 230 includes one or more keys or buttons 212 configured to allow the user to operate and monitor the operation of the TNP system. As is illustrated, there buttons 212a, 212b, and 212c are included. Button 212a can be configured as a power button to turn on/off the pump assembly 230. Button 212b can be configured as a play/pause button for the delivery of negative pressure therapy. For example, pressing the button 212b can cause therapy to start, and pressing the button 212b afterward can cause therapy to pause or end. Button 212c can be configured to lock the display 206 or the buttons 212. For instance, button 212c can be pressed so that the user does not unintentionally alter the delivery of the therapy. Button 212c can be depressed to unlock the controls. In other embodiments, additional buttons can be used or one or more of the illustrated buttons 212a, 212b, or 212c can be omitted. Multiple key presses or sequences of key presses can be used to operate the pump assembly 230.


The pump assembly 230 includes one or more latch recesses 222 formed in the cover. In the illustrated embodiment, two latch recesses 222 can be formed on the sides of the pump assembly 230. The latch recesses 222 can be configured to allow attachment and detachment of the canister 220 using one or more canister latches 221. The pump assembly 230 comprises an air outlet 224 for allowing air removed from the wound cavity 110 to escape. Air entering the pump assembly can be passed through one or more suitable filters, such as antibacterial filters. This can maintain reusability of the pump assembly. The pump assembly 230 includes one or more strap mounts 226 for connecting a carry strap to the pump assembly 230 or for attaching a cradle. In the illustrated embodiment, two strap mounts 226 can be formed on the sides of the pump assembly 230. In some embodiments, various of these features are omitted or various additional features are added to the pump assembly 230.


The canister 220 is configured to hold fluid (e.g., exudate) removed from the wound cavity 110. The canister 220 includes one or more latches 221 for attaching the canister to the pump assembly 230. In the illustrated embodiment, the canister 220 comprises two latches 221 on the sides of the canister. The exterior of the canister 220 can formed from frosted plastic so that the canister is substantially opaque and the contents of the canister and substantially hidden from plain view. The canister 220 comprises a gripping portion 214 formed in a case of the canister. The gripping portion 214 can be configured to allow the user to hold the pump assembly 220, such as during removal of the canister from the apparatus 230, The canister 220 includes a substantially transparent window 216, which can also include graduations of volume. For example, the illustrated 300 mL canister 220 includes graduations of 50 mL, 100 mL, 150 mL, 200 mL, 250 mL, and 300 mL. Other embodiments of the canister can hold different volume of fluid and can include different graduation scale. For example, the canister can be an 800 mL canister. The canister 220 comprises a tubing channel 218 for connecting to the conduit 140. In some embodiments, various of these features, such as the gripping portion 214, are omitted or various additional features are added to the canister 220. Any of the disclosed canisters may include or may omit a solidifier.



FIG. 2B illustrates a rear view of the pump assembly 230 and canister 220 according to some embodiments. The pump assembly 230 comprises a speaker port 232 for producing sound. The pump assembly 230 includes a filter access door 234 with a screw 235 for removing the access door 234, accessing, and replacing one or more filters, such as antibacterial or odor filters. The pump assembly 230 comprises a gripping portion 236 formed in the case of the pump assembly. The gripping portion 236 can be configured to allow the user to hold the pump assembly 230, such as during removal of the canister 220. The pump assembly 230 includes one or more covers 238 configured to as screw covers or feet or protectors for placing the pump assembly 230 on a surface. The covers 230 can be formed out of rubber, silicone, or any other suitable material. The pump assembly 230 comprises a power jack 239 for charging and recharging an internal battery of the pump assembly. The power jack 239 can be a direct current (DC) jack. In some embodiments, the pump assembly can comprise a disposable power source, such as batteries, so that no power jack is needed.


The canister 220 includes one or more feet 244 for placing the canister on a surface. The feet 244 can be formed out of rubber, silicone, or any other suitable material and can be angled at a suitable angle so that the canister 220 remains stable when placed on the surface. The canister 220 comprises a tube mount relief 246 configured to allow one or more tubes to exit to the front of the device. The canister 220 includes a stand or kickstand 248 for supporting the canister when it is placed on a surface. As explained below, the kickstand 248 can pivot between an opened and closed position. In closed position, the kickstand 248 can be latched to the canister 220. The kickstand 248 can be made out of an opaque material, such as plastic, or a transparent material. The kickstand 248 includes a gripping portion 242 formed in the kickstand. The gripping portion 242 can be configured to allow the user to place the kickstand 248 in the closed position. The kickstand 248 comprises a hole 249 to allow the user to place the kickstand in the open position. The hole 249 can be sized to allow the user to extend the kickstand using a finger.



FIG. 2C illustrates a view of the pump assembly 230 separated from the canister 220 according to some embodiments. The pump assembly 230 includes a vacuum attachment, connector, or inlet 252 through which a vacuum pump communicates negative pressure to the canister 220. The pump assembly aspirates fluid, such as gas, from the wound via the inlet 252. The pump assembly 230 may include an access door 256 configured to allow access to one or more serial, parallel, or hybrid data transfer connector interfaces, such as USB, SD, Compact Disc (CD), DVD, FireWire, Thunderbolt, PCI Express, and the like. Additionally or alternatively, one or more serial, parallel, or hybrid data transfer connector interfaces may be accessed through the access door 234. The connector interfaces can be connector ports.


A pump assembly may include one or more additional or alternative access mechanisms, such as illustrated with respect to FIGS. 9A, 9B, and 10, to access one or more serial, parallel, or hybrid data transfer connector interfaces of the pump assembly. FIGS. 9A and 9B illustrate a view of a pump assembly 900 (similar to the pump assembly 230) that has an access door 902 through which one or more connectors, such as a mini USB connector 910, can access one or more serial, parallel, or hybrid data transfer connector interfaces of the pump assembly 900, including a mini USB connector interface 904. FIG. 10 illustrates a view of a pump assembly 1000 (similar to the pump assembly 230) that includes a side access door which has been removed and through which one or more connectors, such as a mini USB connector 1010, can access one or more serial, parallel, or hybrid data transfer connector interfaces of the pump assembly 1000.



FIG. 3A illustrates an electrical component schematic of a pump assembly 300, such as the pump assembly 230, according to some embodiments. Electrical components can operate to accept user input, provide output to the user, operate the pump assembly and the TNP system, provide network connectivity, and so on. Electrical components can be mounted on one or more printed circuit boards (PCBs) that mechanically support and electrically connect electronic components using conductive tracks, pads and other features etched from copper sheets laminated onto a non-conductive substrate. Components, such as capacitors, resistors, or active devices, can be soldered on the PCBs or embedded in the substrate. PCBs can be single sided (one copper layer), double sided (two copper layers) or multi-layer (outer and inner layers), and conductors on different layers can be connected with vias. As is illustrated, the pump assembly can include multiple processors.


The pump assembly can comprise a user interface processor or controller 310 that can function as a main processor and be configured to operate one or more components for accepting user input and providing output to the user, such as the display 206, buttons 212, etc. Input to the pump assembly and output from the pump assembly can controlled by an input/output (I/O) module 320. For example, the I/O module can receive data from one or more ports, such as serial, parallel, hybrid ports, and the like. The processor 310 also receives data from and provides data to one or more expansion modules 360, such as one or more USB ports, SD ports, CD drives, DVD drives, FireWire ports, Thunderbolt ports, PCI Express ports, and the like. The processor 310, along with other controllers or processors, stores data in one or more memory modules 350, which can be internal or external to the processor 310. Any suitable type of memory can be used, including volatile or non-volatile memory, such as RAM, ROM, magnetic memory, solid-state memory, magnetoresistive random-access memory (MRAM), and the like.


In some embodiments, the processor 310 can be a general purpose controller, such as a low-power processor. In other embodiments, the processor 310 can be an application specific processor. The processor 310 can be configured as a “central” processor in the electronic architecture of the pump assembly, and the processor 310 can coordinate the activity of other processors, such as a pump control processor 370, communications processor 330, and one or more additional processors 380 (e.g.; processor for controlling the display 206, processor for controlling the buttons 212, etc.). The processor 310 can run a suitable operating system, such as a Linux, Windows CE, VxVVorks, etc.


The pump control processor 370 can be configured to control the operation of a negative pressure pump 390. The pump 390 can be a suitable pump, such as a diaphragm pump, peristaltic pump, rotary pump, rotary vane pump, scroll pump, screw pump, liquid ring pump, diaphragm pump operated by a piezoelectric transducer, voice coil pump, and the like. The pump control processor 370 can measure pressure in a fluid flow path, using data received from one or more pressure sensors, calculate the rate of fluid flow, and control the pump. The pump control processor 370 can control a pump motor so that a desired level of negative pressure is achieved in the wound cavity 110. The desired level of negative pressure can be pressure set or selected by the user. In various embodiments, the pump control processor 370 controls the pump (e.g., pump motor) using pulse-width modulation (PWM). A control signal for driving the pump can be a 0-100% duty cycle PWM signal. The pump control processor 370 can perform flow rate calculations and detect various conditions in a flow path. The pump control processor 370 can communicate information to the processor 310. The pump control processor 370 can include internal memory or can utilize memory 350. The pump control processor 370 can be a low-power processor.


A communications processor 330 can be configured to provide wired or wireless connectivity. The communications processor 330 can utilize one or more antennas 340 for sending and receiving data. The communications processor 330 can provide one or more of the following types of connections: Global Positioning System (GPS) technology, cellular connectivity (e.g., 2G, 3G, LTE, 4G, 5G, SIM chip), WiFi connectivity, Internet connectivity, and the like. Connectivity can be used for various activities, such as pump assembly location tracking, asset tracking, compliance monitoring, remote selection, uploading of logs, alarms, and other operational data, and adjustment of therapy settings, upgrading of software or firmware, and the like. The communications processor 330 can provide dual GPS/cellular functionality. Cellular functionality can, for example, be 3G functionality. The pump assembly can include a subscriber identity module (SIM) card, and SIM-based positional information can be obtained.


The communications processor 330 can also be electrically coupled to one or more serial, parallel, or hybrid data transfer connector interfaces or another type of interface through which the communications processor 330 can directly receive data or commands without receiving the data or commands through or from the processor 310. For instance, the data transfer connector interfaces can include one or more USB ports, SD ports, CD drives, DVD drives, FireWire ports, Thunderbolt ports, PCI Express ports, and the like. The data transfer connector interfaces can, for instance, be part of the communications processor 330 or part of the input/output (I/O) module 320.


The communications processor 330 can communicate information to the processor 310 and receive information from the processor 310. The communications processor 330 can include internal memory or can utilize memory 350. The communications processor 330 can be a low-power processor.


Using the connectivity provided by the communications processor 330, the device can upload any of the data stored, maintained, or tracked by the pump assembly. The device can also download various operational data, such as therapy selection and parameters, firmware and software patches and upgrades, and the like.



FIG. 3B illustrates example communication between the pump assembly 300 and multiple other devices, including an electronic device 392 (such as a laptop, tablet, smart phone, or another computing device) and a data processing system 394. The electronic device 392 and the data processing system 394 can exchange data or commands (for instance, commands of a Hayes command set) with the pump assembly 300 via one or more of the input/output (I/O) module 320, a serial, parallel, or hybrid data transfer connector interface of the communications processor 330, and the antenna 340. The electronic device 392 can, for example, interrogate or reprogram the communications processor 330. The electronic device 392 may not be supported by a housing of the pump assembly 300. The data processing system 394 may communicate with the pump assembly 300 via a network 396. The network 396 can be a communication network, such as a wired communication network or a wireless communication network like a cellular communication network.


The communications processor 330 can receive and execute an executable command from the electronic device 392 without interrupting wound therapy being performed by the pump assembly 300 and without the processor 310 being operational (for instance, powered). Moreover, the communications processor 330 can receive and execute an executable command from the electronic device 392 that instructs and causes the communications processor 330 to: test an operation of the communications processor 330, transmit the hardware or software version data for the communications processor 330 to the electronic device 392, change a setting associated with operation of the communications processor 330, communicate data via one communication network rather than another communication network, perform an operation associated with a communication network over which the communications processor 330 transmits data, or the like. The communications processor 330 can enter a data mode in which data processed by the communications processor 330 is not executed and a command mode in which data processed by the communications processor 330 is executed. In some implementations, the communication processor 330 can execute certain executable commands (such as those described herein) directly without communicating such commands to or otherwise involving the processor 310. The communication processor 330 can communicate to or otherwise involve the processor 310 for execution of certain other executable commands, such as executable commands that relate to provision of therapy.


In one implementation, the electronic device 392 can be a personal computer (PC) that communicates with the pump assembly 300. The electronic device 392 can be first connected to the pump assembly 300 and the pump assembly 300—or at least the communications processor 330—can be unpowered. The pump assembly 300—or at least the communications processor 330—can then be powered and a wait period of 30 seconds can be initiated and completed. On the electronic device 392, a terminal program (for instance, PuTTY HyperTerminal) can next be opened and connected to a communications port through which the electronic device 392 is connected to the pump assembly 300. The terminal program can subsequently be used to provide executable commands to the communications processor 330, and the terminal program can display any responses from the communications processor 330.



FIG. 4A illustrates exploded view of a pump assembly 400, such as the pump assembly 230, according to some embodiments. The illustrated view can correspond to the front portion of the pump assembly 400. The components of the pump assembly 400 can include; a front enclosure 401, a GPS antenna 402, a status light pipe 403, adhesives 404, a liquid crystal display (LCD) 405, a chassis and LCD circuit board assembly 406, screws 407, a main circuit board assembly 408 (on which the processor 310 and the pump control processor 370 can be mounted in some implementations), screws 409, standoffs 410, a communications circuit board assembly 411 (on which the communications processor 330 can be mounted in some implementations), a negative pressure source 412, a power entry cable 413, a USB cable assembly 414, a subscriber identity module (SIM) card 415, a bottom enclosure 416, a canister connector 417, a canister connector O-ring 418, and a keypad 419. FIGS. 4B-4F illustrate multiple views of the pump assembly 400 according to some embodiments. The dimensions included in FIGS. 4B-4F are provided in inches.


Although FIGS. 4A-4F show particular components included as part of the pump assembly 400, some components may be removed or other components may be added in other implementations.



FIG. 5A illustrates exploded view of a pump assembly 500, such as the pump assembly 230, according to some embodiments. The illustrated view can correspond to the back portion of the pump assembly 500. The illustrated components of the pump assembly 500 can be configured to couple to the components of the pump assembly 400 to form an integral pump assembly. The components of the pump assembly 500 can include: an access door 501 (which can be the same as access door 234), a filter enclosure gasket 502, a filter 503 (for example, antibacterial filter, odor filter, and the like), a mini USB port cover 504, a back enclosure 505, a power entry light pipe 506, a power entry circuit board assembly 507, a USB circuit board assembly 508 (on which the I/O module 320 can be mounted in some implementations), a tubing outlet 509, a clip 510, a battery bracket 511, a battery 512, a speaker assembly 513, a speaker filter 514, a push nut 515, a screw 516 (which can be the same as the screw 235), screws 517, screws 518, and foam tape 519. FIGS. 5B-5E illustrate multiple views of the pump assembly 500 according to some embodiments. The dimensions included in FIGS. 5B-5E are provided in inches.


Although FIGS. 5A-5F show particular components included as part of the pump assembly 500, some components may be removed or other components may be added in other implementations.


Device Electronics and Communication



FIG. 6A illustrates a front of a main PCB assembly 600 of a pump assembly, such as the pump assembly 230, according to some embodiments. The main PCB assembly 600 can, for example, be an embodiment of the main circuit board assembly 408. The main PCB assembly 600 can include a digital signal processor 610 for controlling a source of negative pressure, an electromagnetic compatibility shield 620 for an LED backlight (for example, to protect against high voltages like 12 V rather than 3 V), a shielded battery charger 630, a shielded main microcontroller 640 (which can be similar to or the same as the processor 310), a battery connector 650, and a shielded regulator 660 for digital circuitry. FIG. 6B illustrates a back of the main PCB assembly 600.



FIGS. 7A and 7B illustrate a front and back of a wireless communication PCB assembly 700 of a pump assembly, such as the pump assembly 230, according to some embodiments. The wireless communication PCB assembly 700 can, for example, be an embodiment of the communications circuit board assembly 411. The wireless communication PCB assembly 700 can include an antenna board 710 and a PCB 705 with a shielded modem 720 including a wireless communications controller (which can be similar to or the same as the communications processor 330), and a shielded voltage regulator 730. The antenna board 710 can be wireless mobile communications antenna, such a single-, dual-, tri-, quad-, or the like band antenna for communicating via 2G, 3G, LTE, 4G, or the like and be mounted to the communications PCB 705 with mounting brackets 712. The wireless communication PCB assembly 700 can be electrically coupled via a path 740 to a GPS antenna 750, which can be an embodiment of the GPS antenna 402. In addition, the wireless communications controller can electrically couple to a communications interface that enables communication with the wireless communications controller without communicating through the main PCB assembly 600, such as the shielded main microcontroller 640.



FIG. 8A illustrates multiple communications interfaces of various components 800A of a pump assembly, such as the pump assembly 230. The various components 800A can include a wireless communications controller 810, a main microcontroller 820, and a connector port 830. The wireless communications controller 810 can be an implementation of the wireless communications controller of the shielded modem 720, and the main microcontroller 820 can be an implementation of the shielded main microcontroller 640. The connector port 830 can be connected to an electronic device, such as the electronic device 392, to facilitate direct communication between the electronic device and the wireless communications controller 810.


The wireless communications controller 810 can communicate with the main microcontroller 820 via a first path 812A electrically connecting contacts HIDA_P and HD1l_P and a second path 812B electrically connecting contacts HDA_N to HDA1_N. The wireless communications controller 810 can communicate with the connector port 830 via a third path 814A electrically connecting contacts HDA_P and HDA2_P and a fourth path 814B electrically connecting contacts FIDA_N to HDA2_N. In operation, one of the first and second paths 812A, 812B or the third and fourth paths 814A, 814B may be connected at a time so that either the main microcontroller 820 or the connector port 830 may communicate with the wireless communications controller 810. For example, resistors R16, R17 can be activated or conducting and resistors R14, R15 may not be activated or conducting when the wireless communications controller 810 communicates with the connector port 830, and the resistors R14, R15 can be activated or conducting and the resistors R16, R17 may not be activated or conducting when the wireless communications controller 810 communicates with the main microcontroller 820. In some implementations, resistors R14, R15, R16, and R17 can be replaced with two or more dip switches, relays, or the like to permit connection of the wireless communications controller 810 to the main microcontroller 820 or the connector port 830.



FIG. 8B illustrates multiple communications interfaces of various components 800B of a pump assembly, such as the pump assembly 230. The various components 800B can be similar to the various components 800A with the exception that a first switch 840A and a second switch 840B be used to control the electrical connection of the wireless communications controller 810 to either the main microcontroller 820 or the connector port 830. The first and second switches 840A, 840B can accordingly be considered to adjust a mode of operation of the pump assembly (such as between a normal mode where therapy may be performed and data can be transmitted and received by the main microcontroller 820 via the wireless communications controller 810 and a test mode where cellular or wireless coexistence testing is performed like to send AT commands.


The first and second switches 840A, 840B can, for instance, be part of one or more dual in-line package (DIP) switches. In certain embodiments, the implementation of the various components 800A can be preferred over the implementation of the various components 800B because the first and second switches 840A, 840B may introduce noise or other negative signal artifacts that impede communication with the wireless communications controller 810.


The first and second switches 840A, 840B can, in some implementations, be smart switches, such as analog relay switches, that may be commanded via software. In one example, a display of a pump assembly, such as the display 206, can present a user input that is selected to control a state of one or both of the first and second switches 840A, 840B. In another example, a state of one or both of the first and second switches 840A, 840B can be adjusted via remote communication between a pump assembly and another electronic device. The first and second switches 840A, 840B can be controlled as a serial communication router (for instance, USB, SPI, I2C, or the like), multiplexers, or analog switches. The first and second switches 840A, 840B can be one-time or multi-use fuses in some implementations, which can be desirable in some cases for preprograming code or settings in the wireless communications controller 810 and securing later.


The first and second switches 840A, 840B can be designed so that the pump assembly with the first and second switches 840A, 840B may pass wireless coexistence adjacent channel selectivity testing (for instance, 3G wireless coexistence adjacent channel selectivity testing). The first and second switches 840A, 840B can access the wireless communications controller 810 via another electronic device or a special tool and may be used to analyze or troubleshoot a break in device security. The another electronic device or special tool can moreover send an AT command that allows the another electronic device or special tool to test a carrier for the pump assembly (for example, a cellular network on which the pump assembly communicates using the wireless communications controller 810). In the event of a software or hardware failure or a safety failure, such as to the main microcontroller 820 or another controller of the pump assembly other than the wireless communications controller 810, the first and second switches 840A, 840B can help with analyzing the communication channel between the wireless communications controller 810 and the main microcontroller 820. In some implementations, a SIM card can be connected to the wireless communications controller 810.


Although FIGS. 8A and 8B may describe communication with the wireless communications controller 810, another controller of the pump assembly may be positioned and connected in place of the wireless communications controller 810 enabling the another controller, which may provide alternative or additional functionality relative to the wireless communications controller 810, to communicate with the main microcontroller 820 and the connector port 830.



FIG. 11 illustrates a process 1100 performable by a pump assembly, such as the pump assembly 230. For convenience, the process 1100 is described in the context of components of the pump assembly 300, but may instead be implemented in other systems described herein or by other systems not shown.


At block 1102, the process 1100 can control application of negative pressure. For example, the processor 310 can instruct and cause the pump control processor 370 to start or stop provision of negative pressure with the pump 390.


At block 1104, the process 1100 can communicate therapy data via a communication network. For example, the processor 310 can instruct and cause the communications processor 330 to wirelessly transmit therapy data indicative of a characteristic of wound therapy performed by the pump assembly 300 via the network 396 to the data processing system 394.


At block 1106, the process 1100 can receive an executable command. For example, the communications processor 330 can receive an executable command from the external device 392.


At block 1108, the process 1100 can execute the executable command. For example, the communications processor 330 can execute the executable command causing the communications processor 330 to perform one or more operations, such as to test an operation of the communications processor 330, transmit hardware or software version data for the communications processor 330, change a setting associated with operation of the communications processor 330, or transition from communicating therapy data one communication network to a different communication network. The communications processor 330 moreover may execute the command without the processor 310 processing the executable command or without providing the executable command to the processor 310.


OTHER VARIATIONS AND TERMINOLOGY

The communications processor 330 of FIG. 3A can permit interrogation or reprograming of the communications processor 330 via manual user interactions with the pump assembly 300, such as via user inputs to interface elements (such as, buttons or zones of a touchscreen) of the processor 310 or the input/output (I/O) module 320. In one example, a display of the pump assembly, such as the display 206, can present a terminal program (for instance, PuTTY HyperTerminal). User inputs to the display or one or more other interface elements can be received by the terminal program and used by the terminal program to generate and provide an executable command (such as, an AT command [which may for instance be in accordance with one or more standards like 3GPP TS 34.121 (WCDMA), 3GPP TS 51.010 (GSM without EGRPS) and 3GPP TS51.010 (GSM with EGRPS)] or a command of a Hayes command set) to the communications processor 330 for execution. The terminal program can display any responses from the communications processor 330, such as the results of execution of the executable command. The communications processor 330 can receive and execute the executable command from the terminal program without interrupting wound therapy being performed by the pump assembly 300 or without at least some components or features of the pump assembly 300 (for instance, powered or activated). The executable command may, in some embodiments, instruct and cause the communications processor 330 to; test an operation of the communications processor 330, transmit the hardware or software version data for the communications processor 330 to the display for presentation, change a setting associated with operation of the communications processor 330, communicate data via one communication network rather than another communication network, perform an operation associated with a communication network over which the communications processor 330 transmits data, or the like.


Any value of a threshold, limit, duration, etc. provided herein is not intended to be absolute and, thereby, can be approximate. In addition, any threshold, limit, duration, etc. provided herein can be fixed or varied either automatically or by a user. Furthermore, as is used herein relative terminology such as exceeds, greater than, less than, etc. in relation to a reference value is intended to also encompass being equal to the reference value. For example, exceeding a reference value that is positive can encompass being equal to or greater than the reference value. In addition, as is used herein relative terminology such as exceeds, greater than, less than, etc. in relation to a reference value is intended to also encompass an inverse of the disclosed relationship, such as below, less than, greater than, etc. in relations to the reference value. Moreover, although blocks of the various processes may be described in terms of determining whether a value meets or does not meet a particular threshold, the blocks can be similarly understood, for example, in terms of a value (i) being below or above a threshold or (ii) satisfying or not satisfying a threshold.


Features, materials, characteristics, or groups described in conjunction with a particular aspect, embodiment, or example are to be understood to be applicable to any other aspect, embodiment or example described herein unless incompatible therewith. AH of the features disclosed in this specification (including any accompanying claims, abstract and drawings), or all of the steps of any method or process so disclosed, may be combined in any combination, except combinations where at least some of such features or steps are mutually exclusive. The protection is not restricted to the details of any foregoing embodiments. The protection extends to any novel one, or any novel combination, of the features disclosed in this specification (including any accompanying claims, abstract and drawings), or to any novel one, or any novel combination, of the steps of any method or process so disclosed.


While certain embodiments have been described, these embodiments have been presented by way of example only, and are not intended to limit the scope of protection. Indeed, the novel methods and systems described herein may be embodied in a variety of other forms. Furthermore, various omissions, substitutions and changes in the form of the methods and systems described herein may be made. Those skilled in the art will appreciate that in some embodiments, the actual steps taken in the processes illustrated or disclosed may differ from those shown in the figures. Depending on the embodiment, certain of the steps described above may be removed, others may be added. For example, the actual steps or order of steps taken in the disclosed processes may differ from those shown in the figure. Depending on the embodiment, certain of the steps described above may be removed, others may be added. For instance, the various components illustrated in the figures may be implemented as software or firmware on a processor, controller, ASIC, FPGA, or dedicated hardware. Hardware components, such as processors, ASICs, FPGAs, and the like, can include logic circuitry. Furthermore, the features and attributes of the specific embodiments disclosed above may be combined in different ways to form additional embodiments, all of which fall within the scope of the present disclosure.


Although the present disclosure includes certain embodiments, examples and applications, it will be understood by those skilled in the art that the present disclosure extends beyond the specifically disclosed embodiments to other alternative embodiments or uses and obvious modifications and equivalents thereof, including embodiments which do not provide all of the features and advantages set forth herein. Accordingly, the scope of the present disclosure is not intended to be limited by the specific disclosures of preferred embodiments herein, and may be defined by claims as presented herein or as presented in the future.


Conditional language, such as “can,” “could,” “might,” or “may,” unless specifically stated otherwise, or otherwise understood within the context as used, is generally intended to convey that certain embodiments include, while other embodiments do not include, certain features, elements, or steps. Thus, such conditional language is not generally intended to imply that features, elements, or steps are in any way required for one or more embodiments or that one or more embodiments necessarily include logic for deciding, with or without user input or prompting, whether these features, elements, or steps are included or are to be performed in any particular embodiment. The terms “comprising,” “including,” “having,” and the like are synonymous and are used inclusively, in an open-ended fashion, and do not exclude additional elements, features, acts, operations, and so forth. Also, the term or is used in its inclusive sense (and not in its exclusive sense) so that when used, for example, to connect a list of elements, the term “or” means one, some, or all of the elements in the list. Further, the term “each,” as used herein, in addition to having its ordinary meaning, can mean any subset of a set of elements to which the term “each” is applied.


Conjunctive language such as the phrase “at least one of X, Y, and Z” unless specifically stated otherwise, is otherwise understood with the context as used in general to convey that an item, term, etc. may be either X, Y, or Z. Thus, such conjunctive language is not generally intended to imply that certain embodiments require the presence of at least one of X, at least one of Y, and at least one of Z.


Language of degree used herein, such as the terms “approximately,” “about,” “generally,” and “substantially” as used herein represent a value, amount, or characteristic close to the stated value, amount, or characteristic that still performs a desired function or achieves a desired result. For example, the terms “approximately”, “about”, “generally,” and “substantially” may refer to an amount that is within less than 10% of, within less than 5% of, within less than 1% of, within less than 0.1% of, and within less than 0.01% of the stated amount. As another example, in certain embodiments, the terms “generally parallel” and “substantially parallel” refer to a value, amount, or characteristic that departs from exactly parallel by less than or equal to 15 degrees, 10 degrees, 5 degrees, 3 degrees, 1 degree, or 0.1 degree.


The scope of the present disclosure is not intended to be limited by the specific disclosures of preferred embodiments in this section or elsewhere in this specification, and may be defined by claims as presented in this section or elsewhere in this specification or as presented in the future. The language of the claims is to be interpreted broadly based on the language employed in the claims and not limited to the examples described in the present specification or during the prosecution of the application, which examples are to be construed as non-exclusive.

Claims
  • 1. An apparatus for applying negative pressure to a wound, the apparatus comprising: a housing;a negative pressure source at least partially enclosed by the housing and configured to provide negative pressure via a fluid flow path to a wound dressing;a first circuit board assembly at least partially enclosed by the housing and comprising a first controller configured to control a wound therapy with the wound dressing by activation and deactivation of the negative pressure source;a second circuit board assembly at least partially enclosed by the housing, the second circuit board assembly being separate from the first circuit board assembly and comprising a second controller configured to: communicate therapy data via a communication network, the therapy data being indicative of a characteristic of the wound therapy,receive an executable command from an electronic device separate from the apparatus, andexecute the executable command without providing the executable command to the first controller; andone or more switches configured to electrically connect the first controller to either the second controller for communication or the electronic device for communication.
  • 2. The apparatus of claim 1, wherein the one or more switches are configured to, responsive to a user input, transition from (i) electrically connecting the first controller to the second controller for communication to (ii) electrically connecting the first controller to the electronic device for communication.
  • 3. The apparatus of claim 1, wherein the one or more switches are configured to, responsive to a communication from another electronic device separate from the apparatus, transition from (i) electrically connecting the first controller to the second controller for communication to (ii) electrically connecting the first controller to the electronic device for communication.
  • 4. The apparatus of claim 1, wherein the second controller is configured to receive the executable command from the electronic device via the one or more switches.
  • 5. The apparatus of claim 1, wherein the second controller is configured to receive and execute the executable command without the wound therapy being interrupted.
  • 6. The apparatus of claim 1, wherein the second controller is in a test mode when the one or more switches electrically connect the first controller to the electronic device, and the second controller is in a non-test mode when the one or more switches electrically connect the first controller to the second controller.
  • 7. The apparatus of claim 1, wherein execution of the executable command by the second controller causes the second controller to test an operation of the second controller.
  • 8. The apparatus of claim 1, wherein the second controller is configured to execute the executable command despite the first controller not being operational.
  • 9. The apparatus of claim 1, wherein the executable command comprises a request for hardware or software version data, and execution of the executable command by the second controller causes the second controller to transmit the hardware or software version data to the electronic device.
  • 10. The apparatus of claim 1, wherein execution of the executable command by the second controller causes the second controller to change a setting associated with operation of the second controller.
  • 11. The apparatus of claim 1, wherein execution of the executable command by the second controller causes the second controller to communicate the therapy data via another communication network rather than the communication network.
  • 12. The apparatus of claim 1, wherein the executable command is an attention (AT) command or a command of a Hayes command set.
  • 13. The apparatus of claim 1, wherein the second circuit board assembly comprises a modem that includes the second controller.
  • 14. A method of operating a wound therapy device comprising a first circuit board assembly, a second circuit board assembly separate from the first circuit board assembly, and one or more switches, the method comprising: by a first controller mounted to the first circuit board assembly: controlling application of negative pressure with a pressure source to a wound dressing;by a second controller mounted to the second circuit board assembly: communicating therapy data via a communication network, the therapy data being indicative of a characteristic of a wound therapy performed with the pressure source,receiving an executable command from an electronic device separate from the wound therapy device, andexecuting the executable command without processing the executable command with the first controller; andby the one or more switches: transitioning from electrically connecting the first controller to the second controller for communication to electrically connecting the first controller to the electric device for communication.
  • 15. The method of claim 14, further comprising receiving the executable command from the electronic device via the one or more switches.
  • 16. The method of claim 14, wherein said receiving and executing comprises receiving and executing the executable command without the wound therapy being interrupted.
  • 17. The method of claim 14, wherein said executing comprises executing the executable command to test an operation of the second controller or change a setting associated with operation of the second controller.
  • 18. The method of claim 17, wherein said executing comprises executing the executable command despite the first controller not being operational.
  • 19. The method of claim 17, wherein said transitioning is performed responsive to a user input to the wound therapy device.
  • 20. The method of claim 17, wherein said transitioning is performed responsive to a communication from another electronic device separate from the wound therapy device.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 16/629,190, filed Jan. 7, 2020, which is a U.S. national stage application of International Patent Application No. PCT/US2018/041313, filed Jul. 9, 2018, which claims the benefit of U.S. Provisional Application No. 62/530,480, filed Jul. 10, 2017; the disclosure of which is hereby incorporated by reference in its entirety.

US Referenced Citations (557)
Number Name Date Kind
695270 Beringer Mar 1902 A
3194239 Sullivan et al. Jul 1965 A
4832299 Gorton et al. May 1989 A
5219428 Stern Jun 1993 A
5473536 Wimmer Dec 1995 A
5960403 Brown Sep 1999 A
6055506 Frasca et al. Apr 2000 A
6336900 Alleckson et al. Jan 2002 B1
6353445 Babula et al. Mar 2002 B1
6375614 Braun et al. Apr 2002 B1
6385622 Bouve et al. May 2002 B2
6406426 Reuss et al. Jun 2002 B1
6434572 Derzay et al. Aug 2002 B2
6460041 Lloyd Oct 2002 B2
6574518 Lounsberry et al. Jun 2003 B1
6640145 Hoffberg et al. Oct 2003 B2
6640246 Gary et al. Oct 2003 B1
6675131 Hahn Jan 2004 B2
6681003 Linder et al. Jan 2004 B2
6723046 Lichtenstein et al. Apr 2004 B2
6730024 Freyre et al. May 2004 B2
6747556 Medema et al. Jun 2004 B2
6779024 DeLahuerga Aug 2004 B2
6782285 Birkenbach et al. Aug 2004 B2
6856825 Hahn Feb 2005 B2
6868528 Roberts Mar 2005 B2
6871211 Labounty et al. Mar 2005 B2
6909974 Yung et al. Jun 2005 B2
6912481 Breunissen et al. Jun 2005 B2
6961731 Holbrook Nov 2005 B2
7004915 Boynton et al. Feb 2006 B2
7022113 Lockwood et al. Apr 2006 B2
7051012 Cole et al. May 2006 B2
7062251 Birkett et al. Jun 2006 B2
7066883 Schmidt et al. Jun 2006 B2
7103578 Beck et al. Sep 2006 B2
7108683 Zamierowski Sep 2006 B2
7120488 Nova et al. Oct 2006 B2
7133869 Bryan et al. Nov 2006 B2
7167858 Naeymi-Rad et al. Jan 2007 B2
7212829 Lau et al. May 2007 B1
7264591 Brown Sep 2007 B2
7300418 Zaleski Nov 2007 B2
7304573 Postma Dec 2007 B2
7311665 Hawthorne et al. Dec 2007 B2
7333002 Bixler et al. Feb 2008 B2
7353179 Ott et al. Apr 2008 B2
7384267 Franks et al. Jun 2008 B1
7430598 Raden et al. Sep 2008 B2
7430608 Noonan et al. Sep 2008 B2
7438705 Karpowicz et al. Oct 2008 B2
7451002 Choubey Nov 2008 B2
7457804 Uber et al. Nov 2008 B2
7460872 Millard et al. Dec 2008 B2
7534240 Johnson May 2009 B1
7598855 Scalisi et al. Oct 2009 B2
7608066 Vogel Oct 2009 B2
7627334 Cohen et al. Dec 2009 B2
7649449 Fenske et al. Jan 2010 B2
7671733 McNeal et al. Mar 2010 B2
7684999 Brown Mar 2010 B2
7698156 Martucci et al. Apr 2010 B2
7734764 Weiner et al. Jun 2010 B2
7749164 Davis Jul 2010 B2
7758555 Kelch et al. Jul 2010 B2
7779153 Van Den Heuvel et al. Aug 2010 B2
7789828 Clapp Sep 2010 B2
7794438 Henley et al. Sep 2010 B2
7827148 Mori et al. Nov 2010 B2
7865375 Lancaster et al. Jan 2011 B2
7889069 Fifolt et al. Feb 2011 B2
7890887 Linardos et al. Feb 2011 B1
7912823 Ferrari et al. Mar 2011 B2
7925603 Laidig et al. Apr 2011 B1
7933817 Radl et al. Apr 2011 B2
7976519 Bubb et al. Jul 2011 B2
7981098 Boehringer et al. Jul 2011 B2
7988850 Roncadi et al. Aug 2011 B2
8015443 Adachi Sep 2011 B2
8015972 Pirzada Sep 2011 B2
8019618 Brown Sep 2011 B2
8036925 Choubey Oct 2011 B2
8054950 Hung et al. Nov 2011 B1
8069057 Choubey et al. Nov 2011 B2
8094009 Allen et al. Jan 2012 B2
8126735 Dicks et al. Feb 2012 B2
8130095 Allen et al. Mar 2012 B2
8131472 Chow et al. Mar 2012 B2
8180750 Wilmering et al. May 2012 B2
8190445 Kuth et al. May 2012 B2
8190448 Bajars et al. May 2012 B2
8228188 Key et al. Jul 2012 B2
8246606 Stevenson et al. Aug 2012 B2
8249894 Brown Aug 2012 B2
8255241 Cafer Aug 2012 B2
8260630 Brown Sep 2012 B2
8280682 Vock et al. Oct 2012 B2
8284046 Allen et al. Oct 2012 B2
8290792 Sekura Oct 2012 B2
8291337 Gannin et al. Oct 2012 B2
8323263 Wood et al. Dec 2012 B2
8332233 Ott et al. Dec 2012 B2
8332236 Yurko et al. Dec 2012 B2
8334768 Eaton et al. Dec 2012 B2
8337482 Wood et al. Dec 2012 B2
8360975 Schwieterman et al. Jan 2013 B1
8400295 Khaira Mar 2013 B1
8422377 Weiner et al. Apr 2013 B2
8424517 Sutherland et al. Apr 2013 B2
8436871 Alberte May 2013 B2
8439882 Kelch May 2013 B2
8457740 Osche Jun 2013 B2
8480641 Jacobs Jul 2013 B2
8515776 Schoenberg Aug 2013 B2
8532764 Duke Sep 2013 B2
8540688 Eckstein et al. Sep 2013 B2
8545483 Schwabe et al. Oct 2013 B2
8554195 Rao Oct 2013 B2
8554902 Ebert et al. Oct 2013 B2
8558964 Bedingfield Oct 2013 B2
8560082 Wei Oct 2013 B2
8577694 Kanaan Nov 2013 B2
8595553 Goertler et al. Nov 2013 B2
8600777 Schoenberg et al. Dec 2013 B2
8626342 Williams et al. Jan 2014 B2
8626526 Lemke et al. Jan 2014 B2
8630660 Ray et al. Jan 2014 B2
8632485 Schlaeper et al. Jan 2014 B2
8641693 Locke et al. Feb 2014 B2
8659420 Salvat et al. Feb 2014 B2
8676597 Buehler et al. Mar 2014 B2
8689008 Rangadass et al. Apr 2014 B2
8694600 Gaines et al. Apr 2014 B2
8706537 Young et al. Apr 2014 B1
8725528 Locke et al. May 2014 B2
8756078 Collins, Jr. et al. Jun 2014 B2
8757485 Drees et al. Jun 2014 B2
8758315 Chen et al. Jun 2014 B2
8768441 De Zwart et al. Jul 2014 B2
8769625 Wang et al. Jul 2014 B2
8781847 Simms et al. Jul 2014 B2
8795171 Adamczyk Aug 2014 B2
8795244 Randolph et al. Aug 2014 B2
8838136 Carnes et al. Sep 2014 B2
8862393 Zhou et al. Oct 2014 B2
8868794 Masoud et al. Oct 2014 B2
8874035 Sherman et al. Oct 2014 B2
8887100 Cook et al. Nov 2014 B1
8890656 Pendse Nov 2014 B2
8897198 Gaines et al. Nov 2014 B2
8902278 Pinter et al. Dec 2014 B2
8905959 Basaglia Dec 2014 B2
8909595 Gandy et al. Dec 2014 B2
8912897 Carnes Dec 2014 B2
8922377 Carnes Dec 2014 B2
8945073 Croizat et al. Feb 2015 B2
8947237 Margon et al. Feb 2015 B2
8978026 Charlton et al. Mar 2015 B2
8996393 Sobie Mar 2015 B2
9047648 Lekutai et al. Jun 2015 B1
9058634 Buan et al. Jun 2015 B2
9081885 Bangera et al. Jul 2015 B2
9087141 Huang et al. Jul 2015 B2
9092705 Zhuang Jul 2015 B2
9098114 Potter et al. Aug 2015 B2
9105006 Williamson Aug 2015 B2
9114054 Bennett Aug 2015 B2
9117012 Basaglia Aug 2015 B2
9135398 Kaib et al. Sep 2015 B2
9141270 Stuart et al. Sep 2015 B1
9159148 Boyer et al. Oct 2015 B2
9215516 Carnes et al. Dec 2015 B2
9215581 Julian et al. Dec 2015 B2
9230420 Lee et al. Jan 2016 B2
9268827 Fernandez Feb 2016 B2
9286443 Ford et al. Mar 2016 B2
9323893 Berry et al. Apr 2016 B2
9332363 Jain et al. May 2016 B2
9338819 Meng et al. May 2016 B2
9424020 Borges et al. Aug 2016 B2
9427159 Chang Aug 2016 B2
9436645 Al-Ali et al. Sep 2016 B2
9436800 Forrester Sep 2016 B2
9439584 De Vries et al. Sep 2016 B1
9460431 Curry Oct 2016 B2
9474679 Locke et al. Oct 2016 B2
9483614 Ash et al. Nov 2016 B2
9539373 Jones et al. Jan 2017 B2
9545466 Locke et al. Jan 2017 B2
9558331 Orona et al. Jan 2017 B2
9585565 Carnes Mar 2017 B2
9589247 Bolene et al. Mar 2017 B2
9602952 Kang et al. Mar 2017 B2
9629986 Patel et al. Apr 2017 B2
9658066 Yuen et al. May 2017 B2
9662438 Kamen et al. May 2017 B2
9687618 Steinhauer et al. Jun 2017 B2
9693691 Johnson Jul 2017 B2
9700462 DeBusk et al. Jul 2017 B2
9716757 Fernandes Jul 2017 B2
9740825 Sansale et al. Aug 2017 B2
9741084 Holmes et al. Aug 2017 B2
9787842 Brooksby et al. Oct 2017 B1
9792660 Cannon et al. Oct 2017 B2
9817948 Swank Nov 2017 B2
9818164 Nolte et al. Nov 2017 B2
9838645 Hyde et al. Dec 2017 B2
9864066 Park et al. Jan 2018 B2
9878081 Leiendecker et al. Jan 2018 B2
9905123 Lawhorn Feb 2018 B2
9928478 Ragusky et al. Mar 2018 B2
9974492 Dicks et al. May 2018 B1
9990466 DeBusk et al. Jun 2018 B2
9996681 Suarez et al. Jun 2018 B2
10049346 Jensen et al. Aug 2018 B2
10061894 Sethumadhavan et al. Aug 2018 B2
10095649 Joshua et al. Oct 2018 B2
10127357 Whiting et al. Nov 2018 B2
10152575 Sexton et al. Dec 2018 B2
10173008 Simpson et al. Jan 2019 B2
10185834 Adam et al. Jan 2019 B2
10207031 Toth Feb 2019 B2
10328188 Deutsch et al. Jun 2019 B2
11712508 Gregory Aug 2023 B2
20020087360 Pettit Jul 2002 A1
20020128804 Geva Sep 2002 A1
20020128869 Kuth Sep 2002 A1
20020135336 Zhou et al. Sep 2002 A1
20020177757 Britton Nov 2002 A1
20020184055 Naghavi et al. Dec 2002 A1
20030009244 Engleson et al. Jan 2003 A1
20030018736 Christ et al. Jan 2003 A1
20030105649 Sheiner et al. Jun 2003 A1
20030182158 Son Sep 2003 A1
20030221687 Kaigler Dec 2003 A1
20030229518 Abraham-Fuchs et al. Dec 2003 A1
20040006492 Watanabe Jan 2004 A1
20040054775 Poliac et al. Mar 2004 A1
20040078223 Sacco et al. Apr 2004 A1
20040143458 Pulkkinen et al. Jul 2004 A1
20040158193 Bui et al. Aug 2004 A1
20040167802 Takada et al. Aug 2004 A1
20040167804 Simpson et al. Aug 2004 A1
20040172301 Mihai et al. Sep 2004 A1
20040181433 Blair Sep 2004 A1
20040193449 Wildman et al. Sep 2004 A1
20040204962 Howser et al. Oct 2004 A1
20050033124 Kelly et al. Feb 2005 A1
20050055225 Mehl Mar 2005 A1
20050055242 Bello et al. Mar 2005 A1
20050055244 Mullan et al. Mar 2005 A1
20050060211 Xiao et al. Mar 2005 A1
20050065817 Mihai et al. Mar 2005 A1
20050097200 Denning et al. May 2005 A1
20050102167 Kapoor May 2005 A1
20050108046 Craft May 2005 A1
20050108057 Cohen et al. May 2005 A1
20050114176 Dominick et al. May 2005 A1
20050119914 Batch Jun 2005 A1
20050222873 Nephin et al. Oct 2005 A1
20050240111 Chung Oct 2005 A1
20050283382 Donoghue et al. Dec 2005 A1
20060004604 White Jan 2006 A1
20060064323 Alleckson et al. Mar 2006 A1
20060085393 Modesitt Apr 2006 A1
20060089539 Miodownik et al. Apr 2006 A1
20060095853 Amyot et al. May 2006 A1
20060155584 Aggarwal Jul 2006 A1
20060161460 Smitherman et al. Jul 2006 A1
20060190130 Fedor et al. Aug 2006 A1
20060195843 Hall Aug 2006 A1
20060224051 Teller et al. Oct 2006 A1
20060246922 Gasbarro et al. Nov 2006 A1
20070136099 Neligh et al. Jun 2007 A1
20070156456 McGillin et al. Jul 2007 A1
20070197881 Wolf et al. Aug 2007 A1
20070219826 Brodsky et al. Sep 2007 A1
20070255116 Mehta et al. Nov 2007 A1
20070271298 Juang et al. Nov 2007 A1
20080009681 Al Hussiny Jan 2008 A1
20080086357 Choubey et al. Apr 2008 A1
20080091659 McFaul Apr 2008 A1
20080119705 Patel et al. May 2008 A1
20080126126 Ballai May 2008 A1
20080140160 Goetz et al. Jun 2008 A1
20080167534 Young et al. Jul 2008 A1
20080177579 Dehaan Jul 2008 A1
20080221396 Garces et al. Sep 2008 A1
20080242945 Gugliotti et al. Oct 2008 A1
20080312953 Claus Dec 2008 A1
20090037220 Chambers et al. Feb 2009 A1
20090048492 Rantala et al. Feb 2009 A1
20090048865 Breazeale, Jr. Feb 2009 A1
20090097623 Bharadwaj Apr 2009 A1
20090099866 Newman Apr 2009 A1
20090099867 Newman Apr 2009 A1
20090115663 Brown et al. May 2009 A1
20090118591 Kim et al. May 2009 A1
20090125331 Pamsgaard et al. May 2009 A1
20090136909 Asukai et al. May 2009 A1
20090144091 Rago Jun 2009 A1
20090157429 Lee et al. Jun 2009 A1
20090163774 Thatha et al. Jun 2009 A1
20090171166 Amundson et al. Jul 2009 A1
20090177495 Abousy et al. Jul 2009 A1
20090187424 Grabowski Jul 2009 A1
20090204434 Breazeale, Jr. Aug 2009 A1
20090204435 Gale Aug 2009 A1
20090205042 Zhou et al. Aug 2009 A1
20090224889 Aggarwal et al. Sep 2009 A1
20090270833 DeBelser et al. Oct 2009 A1
20090281822 Warner et al. Nov 2009 A1
20090281830 McNames et al. Nov 2009 A1
20090281867 Sievenpiper et al. Nov 2009 A1
20090326339 Horvitz Dec 2009 A1
20090327102 Maniar et al. Dec 2009 A1
20100001838 Miodownik et al. Jan 2010 A1
20100017471 Brown et al. Jan 2010 A1
20100022848 Lee et al. Jan 2010 A1
20100022990 Karpowicz et al. Jan 2010 A1
20100030302 Blowers et al. Feb 2010 A1
20100036333 Schenk, III et al. Feb 2010 A1
20100090004 Sands et al. Apr 2010 A1
20100106528 Brackett et al. Apr 2010 A1
20100113908 Vargas et al. May 2010 A1
20100145161 Niyato et al. Jun 2010 A1
20100222645 Nadler et al. Sep 2010 A1
20100234708 Buck et al. Sep 2010 A1
20100255876 Jordan et al. Oct 2010 A1
20110004188 Shekalim Jan 2011 A1
20110066110 Fathallah et al. Mar 2011 A1
20110071844 Cannon et al. Mar 2011 A1
20110073107 Rodman et al. Mar 2011 A1
20110077605 Karpowicz et al. Mar 2011 A1
20110106561 Eaton, Jr. et al. May 2011 A1
20110137759 Wellington et al. Jun 2011 A1
20110145018 Fotsch et al. Jun 2011 A1
20110173028 Bond Jul 2011 A1
20110184754 Park et al. Jul 2011 A1
20110225008 Elkouh et al. Sep 2011 A1
20110225499 Lu Sep 2011 A1
20110246219 Smith et al. Oct 2011 A1
20110275353 Liu Nov 2011 A1
20110288878 Blair Nov 2011 A1
20120029312 Beaudry et al. Feb 2012 A1
20120029313 Burdett et al. Feb 2012 A1
20120032819 Chae et al. Feb 2012 A1
20120035427 Friedman et al. Feb 2012 A1
20120077605 Nakagaito et al. Mar 2012 A1
20120081225 Waugh et al. Apr 2012 A1
20120089369 Abuzeni et al. Apr 2012 A1
20120123323 Kagan et al. May 2012 A1
20120123796 McFaul May 2012 A1
20120157889 Tanis et al. Jun 2012 A1
20120181405 Zlatic et al. Jul 2012 A1
20120182143 Gaines et al. Jul 2012 A1
20120191475 Pandey Jul 2012 A1
20120212455 Kloeffel Aug 2012 A1
20120215455 Patil et al. Aug 2012 A1
20120259651 Mallon et al. Oct 2012 A1
20120271256 Locke et al. Oct 2012 A1
20120290217 Shoval et al. Nov 2012 A1
20120295566 Collins et al. Nov 2012 A1
20120310205 Lee et al. Dec 2012 A1
20130018355 Brand et al. Jan 2013 A1
20130035615 Hsieh Feb 2013 A1
20130045764 Vik et al. Feb 2013 A1
20130073303 Hsu Mar 2013 A1
20130076528 Boettner et al. Mar 2013 A1
20130087609 Nichol et al. Apr 2013 A1
20130090949 Tibebu Apr 2013 A1
20130103419 Beaudry Apr 2013 A1
20130124227 Ellis May 2013 A1
20130132855 Manicka et al. May 2013 A1
20130150686 Fronterhouse et al. Jun 2013 A1
20130150698 Hsu et al. Jun 2013 A1
20130151274 Bage et al. Jun 2013 A1
20130157571 Wondka et al. Jun 2013 A1
20130159456 Daoud et al. Jun 2013 A1
20130160082 Miller Jun 2013 A1
20130186405 Krzyzanowski et al. Jul 2013 A1
20130190903 Balakrishnan et al. Jul 2013 A1
20130191513 Kamen et al. Jul 2013 A1
20130196703 Masoud et al. Aug 2013 A1
20130204106 Bennett Aug 2013 A1
20130211206 Sands et al. Aug 2013 A1
20130211854 Wagstaff Aug 2013 A1
20130212168 Bonasera et al. Aug 2013 A1
20130214925 Weiss Aug 2013 A1
20130218053 Kaiser et al. Aug 2013 A1
20130226607 Woody et al. Aug 2013 A1
20130227128 Wagstaff Aug 2013 A1
20130231596 Hornbach et al. Sep 2013 A1
20130245387 Patel Sep 2013 A1
20130253952 Burke et al. Sep 2013 A1
20130255681 Batch et al. Oct 2013 A1
20130267919 Caso et al. Oct 2013 A1
20130268283 Vann et al. Oct 2013 A1
20130271556 Ross et al. Oct 2013 A1
20130282395 Rustgi et al. Oct 2013 A1
20130285837 Uchida Oct 2013 A1
20130297350 Gross et al. Nov 2013 A1
20130304489 Miller Nov 2013 A1
20130310726 Miller et al. Nov 2013 A1
20130317753 Kamen et al. Nov 2013 A1
20130325508 Johnson et al. Dec 2013 A1
20130331748 Wright et al. Dec 2013 A1
20130332197 Hinkel Dec 2013 A1
20130335233 Kamar et al. Dec 2013 A1
20130339049 Blumberg, Jr. et al. Dec 2013 A1
20130345524 Meyer et al. Dec 2013 A1
20140002234 Alwan Jan 2014 A1
20140005618 Locke et al. Jan 2014 A1
20140028464 Garibaldi Jan 2014 A1
20140031884 Elghazzawi Jan 2014 A1
20140032231 Semen et al. Jan 2014 A1
20140058714 Boyer Feb 2014 A1
20140087762 Galvin et al. Mar 2014 A1
20140108033 Akbay et al. Apr 2014 A1
20140108034 Akbay et al. Apr 2014 A1
20140108035 Akbay et al. Apr 2014 A1
20140129250 Daniel et al. May 2014 A1
20140148138 Chou May 2014 A1
20140163919 Manigel et al. Jun 2014 A1
20140171753 Montejo et al. Jun 2014 A1
20140187888 Hatziantoniou Jul 2014 A1
20140207090 Jian Jul 2014 A1
20140222446 Ash et al. Aug 2014 A1
20140235975 Carnes Aug 2014 A1
20140244285 Hinkle et al. Aug 2014 A1
20140244301 Lee et al. Aug 2014 A1
20140244307 Shutko et al. Aug 2014 A1
20140266713 Sehgal et al. Sep 2014 A1
20140275876 Hansen et al. Sep 2014 A1
20140278502 Laskin Sep 2014 A1
20140280882 Lacerte et al. Sep 2014 A1
20140297299 Lester, IV Oct 2014 A1
20140316819 Dunsirn et al. Oct 2014 A1
20140350966 Khatana et al. Nov 2014 A1
20140366878 Baron Dec 2014 A1
20140372147 White Dec 2014 A1
20140372522 Orona et al. Dec 2014 A1
20140375470 Malveaux Dec 2014 A1
20140378895 Barack Dec 2014 A1
20150012290 Inciardi et al. Jan 2015 A1
20150019237 Doyle et al. Jan 2015 A1
20150019257 Doyle et al. Jan 2015 A1
20150025486 Hu et al. Jan 2015 A1
20150046137 Zeilinger Feb 2015 A1
20150066531 Jacobson et al. Mar 2015 A1
20150072613 Swanson Mar 2015 A1
20150094830 Lipoma et al. Apr 2015 A1
20150095056 Ryan et al. Apr 2015 A1
20150095059 Yegge et al. Apr 2015 A1
20150095066 Ryan et al. Apr 2015 A1
20150095068 Ryan et al. Apr 2015 A1
20150100340 Folsom et al. Apr 2015 A1
20150112707 Manice et al. Apr 2015 A1
20150118662 Ellison et al. Apr 2015 A1
20150119652 Hyde et al. Apr 2015 A1
20150120318 Toyama Apr 2015 A1
20150133829 DeBusk et al. May 2015 A1
20150143300 Zhang et al. May 2015 A1
20150164323 Holtzclaw Jun 2015 A1
20150164376 Huang Jun 2015 A1
20150186615 Armor et al. Jul 2015 A1
20150189001 Lee et al. Jul 2015 A1
20150227716 Ryan et al. Aug 2015 A1
20150227717 Ryan et al. Aug 2015 A1
20150234557 Dorn Aug 2015 A1
20150234995 Casady et al. Aug 2015 A1
20150242578 Siemon Aug 2015 A1
20150242583 Edson Aug 2015 A1
20150254403 Laperna Sep 2015 A1
20150257643 Watson et al. Sep 2015 A1
20150261920 Blick Sep 2015 A1
20150269323 Ginsburg Sep 2015 A1
20150286970 Dickerson et al. Oct 2015 A1
20150304478 Kim et al. Oct 2015 A1
20150310182 Henze et al. Oct 2015 A1
20150324943 Han et al. Nov 2015 A1
20150339445 Gruby et al. Nov 2015 A1
20150343188 Allan et al. Dec 2015 A1
20150363058 Chung et al. Dec 2015 A1
20150370984 Russell et al. Dec 2015 A1
20150370997 Krongrad et al. Dec 2015 A1
20150379441 Syed et al. Dec 2015 A1
20160004824 Stanton et al. Jan 2016 A1
20160018963 Robbins et al. Jan 2016 A1
20160042154 Goldberg et al. Feb 2016 A1
20160044141 Pfutzenreuter et al. Feb 2016 A1
20160055310 Bentley et al. Feb 2016 A1
20160058286 Joshua et al. Mar 2016 A1
20160063210 Bardi et al. Mar 2016 A1
20160066864 Frieder et al. Mar 2016 A1
20160080365 Baker et al. Mar 2016 A1
20160085415 Humphrys et al. Mar 2016 A1
20160098524 Himmelstein Apr 2016 A1
20160110507 Abbo Apr 2016 A1
20160128571 Adler May 2016 A1
20160129186 Douglas et al. May 2016 A1
20160135752 Beaumont May 2016 A1
20160142443 Ting et al. May 2016 A1
20160151015 Condurso et al. Jun 2016 A1
20160154936 Kalathil Jun 2016 A1
20160154943 Cho et al. Jun 2016 A1
20160171866 Dupasquier et al. Jun 2016 A1
20160180031 Slater Jun 2016 A1
20160184497 Phillips et al. Jun 2016 A1
20160196399 Bonhomme Jul 2016 A1
20160203275 Benjamin et al. Jul 2016 A1
20160203283 Baruah et al. Jul 2016 A1
20160209837 Kim Jul 2016 A1
20160212577 Dor et al. Jul 2016 A1
20160217433 Walton et al. Jul 2016 A1
20160246943 Lake et al. Aug 2016 A1
20160260035 Crooks et al. Sep 2016 A1
20160287189 Modai et al. Oct 2016 A1
20160308969 Aihara et al. Oct 2016 A1
20160321404 Ginsburg Nov 2016 A1
20160321422 Albright Nov 2016 A1
20170007494 Rock et al. Jan 2017 A1
20170014028 Clear, Jr. Jan 2017 A1
20170017765 Yegge et al. Jan 2017 A1
20170032648 McClain et al. Feb 2017 A1
20170046503 Cho et al. Feb 2017 A1
20170053073 Allen et al. Feb 2017 A1
20170055205 Morris et al. Feb 2017 A1
20170068781 Zasowski et al. Mar 2017 A1
20170074717 Pilkington et al. Mar 2017 A1
20170078396 Haas et al. Mar 2017 A1
20170116373 Ginsburg et al. Apr 2017 A1
20170140120 Thrower May 2017 A1
20170150939 Shah Jun 2017 A1
20170193181 Carter et al. Jul 2017 A1
20170212995 Ingmanson Jul 2017 A1
20170257682 Shtalryd Sep 2017 A1
20170270533 Barton et al. Sep 2017 A1
20170273116 Elghazzawi Sep 2017 A1
20170327371 Bai et al. Nov 2017 A1
20170372010 Doherty et al. Dec 2017 A1
20180004908 Barrus et al. Jan 2018 A1
20180052454 Magno et al. Feb 2018 A1
20180121629 Dyer et al. May 2018 A1
20180139572 Hansen May 2018 A1
20180144817 Lofgren et al. May 2018 A1
20180158545 Blomquist Jun 2018 A1
20180160907 Verma Jun 2018 A1
20180181714 Pillarisetty et al. Jun 2018 A1
20180233016 Daniel et al. Aug 2018 A1
20180233221 Blomquist Aug 2018 A1
20180279880 Bacchi Oct 2018 A1
20180286502 Lane et al. Oct 2018 A1
20180308569 Luellen Oct 2018 A1
20180308573 Hochrein et al. Oct 2018 A1
20180315492 Bishop et al. Nov 2018 A1
20180322944 Valdizan Nov 2018 A1
Foreign Referenced Citations (244)
Number Date Country
102961815 Mar 2013 CN
104721892 Jun 2015 CN
102010036405 Jan 2012 DE
0980227 Feb 2000 EP
0566381 Jul 2002 EP
1231965 Aug 2002 EP
1291802 Mar 2003 EP
1309960 May 2003 EP
0814864 Dec 2003 EP
1407624 Apr 2004 EP
1011420 Dec 2004 EP
1495713 Jan 2005 EP
1524619 Apr 2005 EP
1540557 Jun 2005 EP
1579367 Sep 2005 EP
1587017 Oct 2005 EP
1788503 May 2007 EP
1839244 Oct 2007 EP
1839615 Oct 2007 EP
1857950 Nov 2007 EP
1870068 Dec 2007 EP
1904964 Apr 2008 EP
1934852 Jun 2008 EP
1975828 Oct 2008 EP
1993435 Nov 2008 EP
2038786 Mar 2009 EP
2040604 Apr 2009 EP
2092470 Aug 2009 EP
2146297 Jan 2010 EP
2172859 Apr 2010 EP
2214552 Aug 2010 EP
2218478 Aug 2010 EP
1404213 Mar 2011 EP
1247229 Apr 2011 EP
1406540 Jun 2011 EP
1812094 Aug 2011 EP
2384472 Nov 2011 EP
2226002 Jan 2012 EP
1610494 Mar 2012 EP
1248660 Apr 2012 EP
2023800 Apr 2012 EP
2451513 May 2012 EP
1248661 Aug 2012 EP
2488977 Aug 2012 EP
2562665 Feb 2013 EP
2619723 Jul 2013 EP
1881784 Oct 2013 EP
2664194 Nov 2013 EP
2743850 Jun 2014 EP
2745204 Jun 2014 EP
1684146 Jul 2014 EP
2795492 Oct 2014 EP
2841895 Mar 2015 EP
2850771 Mar 2015 EP
2876567 May 2015 EP
2891999 Jul 2015 EP
2894581 Jul 2015 EP
2906101 Aug 2015 EP
2945084 Nov 2015 EP
2962266 Jan 2016 EP
2968829 Jan 2016 EP
2973089 Jan 2016 EP
3000082 Mar 2016 EP
3010398 Apr 2016 EP
3054389 Aug 2016 EP
3070628 Sep 2016 EP
3078010 Oct 2016 EP
3096113 Nov 2016 EP
2563437 Mar 2017 EP
2773393 Mar 2017 EP
3134854 Mar 2017 EP
3027242 Apr 2017 EP
2556650 May 2017 EP
3174569 Jun 2017 EP
2632407 Aug 2017 EP
3209358 Aug 2017 EP
3041571 Sep 2017 EP
2856767 Nov 2017 EP
3252635 Dec 2017 EP
2320971 May 2018 EP
2335173 May 2018 EP
3100188 Jun 2018 EP
3330973 Jun 2018 EP
3352174 Jul 2018 EP
2440112 Oct 2018 EP
3400549 Nov 2018 EP
2992500 Dec 2018 EP
2597584 Jan 2019 EP
3219340 Jan 2019 EP
2890456 Feb 2019 EP
3377130 Apr 2019 EP
2881875 May 2019 EP
2836269 Aug 2019 EP
2409951 Jul 2005 GB
2436160 Sep 2007 GB
2449400 Nov 2008 GB
2456708 Jul 2009 GB
2423178 May 2010 GB
2475091 May 2011 GB
2488904 Sep 2012 GB
2446923 May 2013 GB
2499986 Sep 2013 GB
2491946 Aug 2014 GB
2499873 May 2016 GB
2533910 Jul 2016 GB
2541286 Feb 2017 GB
2550576 Jun 2018 GB
WO-9627163 Sep 1996 WO
WO-9744745 Nov 1997 WO
WO-9924927 May 1999 WO
WO-9963886 Dec 1999 WO
WO-0032088 Jun 2000 WO
WO-0060522 Oct 2000 WO
WO-0133457 May 2001 WO
WO-0181829 Nov 2001 WO
WO-0217075 Feb 2002 WO
WO-0233577 Apr 2002 WO
WO-02078594 Oct 2002 WO
WO-02101713 Dec 2002 WO
WO-03054668 Jul 2003 WO
WO-2004057514 Jul 2004 WO
WO-2004074457 Sep 2004 WO
WO-2005022349 Mar 2005 WO
WO-2005031632 Apr 2005 WO
WO-2005036447 Apr 2005 WO
WO-2005045461 May 2005 WO
WO-2005053793 Jun 2005 WO
WO-2005057466 Jun 2005 WO
WO-2005083619 Sep 2005 WO
WO-2005101282 Oct 2005 WO
WO-2005109297 Nov 2005 WO
WO-2005120097 Dec 2005 WO
WO-2006021154 Mar 2006 WO
WO-2006066583 Jun 2006 WO
WO-2006066585 Jun 2006 WO
WO-2006071711 Jul 2006 WO
WO-2006099120 Sep 2006 WO
WO-2006108304 Oct 2006 WO
WO-2006108858 Oct 2006 WO
WO-2006111109 Oct 2006 WO
WO-2007027490 Mar 2007 WO
WO-2007035646 Mar 2007 WO
WO-2007127879 Nov 2007 WO
WO-2007133478 Nov 2007 WO
WO-2007137869 Dec 2007 WO
WO-2008010012 Jan 2008 WO
WO-2008036344 Mar 2008 WO
WO-2008062382 May 2008 WO
WO-2008116295 Oct 2008 WO
WO-2008150633 Dec 2008 WO
WO-2009140669 Nov 2009 WO
WO-2010017484 Feb 2010 WO
WO-2010025166 Mar 2010 WO
WO-2010025467 Mar 2010 WO
WO-2010078558 Jul 2010 WO
WO-2010085033 Jul 2010 WO
WO-2010132617 Nov 2010 WO
WO-2010145780 Dec 2010 WO
WO-2011005633 Jan 2011 WO
WO-2011023384 Mar 2011 WO
WO-2011039676 Apr 2011 WO
WO-2011046860 Apr 2011 WO
WO-2011047334 Apr 2011 WO
WO-2011123933 Oct 2011 WO
WO-2011137230 Nov 2011 WO
WO-2012051278 Apr 2012 WO
WO-2012127281 Sep 2012 WO
WO-2013026999 Feb 2013 WO
WO-2013036853 Mar 2013 WO
WO-2013061887 May 2013 WO
WO-2013102855 Jul 2013 WO
WO-2013109517 Jul 2013 WO
WO-2013138182 Sep 2013 WO
WO-2013141870 Sep 2013 WO
WO-2013155193 Oct 2013 WO
WO-2013175076 Nov 2013 WO
WO-2014015215 Jan 2014 WO
WO-2014018786 Jan 2014 WO
WO-2014075494 May 2014 WO
WO-2014089086 Jun 2014 WO
WO-2014100036 Jun 2014 WO
WO-2014100687 Jun 2014 WO
WO-2014106056 Jul 2014 WO
WO-2014123846 Aug 2014 WO
WO-2014133822 Sep 2014 WO
WO-2014141221 Sep 2014 WO
WO-2014145496 Sep 2014 WO
WO-2014150255 Sep 2014 WO
WO-2014152963 Sep 2014 WO
WO-2014189070 Nov 2014 WO
WO-2014009876 Dec 2014 WO
WO-2015019273 Feb 2015 WO
WO-2015025482 Feb 2015 WO
WO-2015026387 Feb 2015 WO
WO-2015050816 Apr 2015 WO
WO-2015078112 Jun 2015 WO
WO-2015085249 Jun 2015 WO
WO-2015091070 Jun 2015 WO
WO-2015124670 Aug 2015 WO
WO-2015132528 Sep 2015 WO
WO-2015140801 Sep 2015 WO
WO-2015143099 Sep 2015 WO
WO-2015145455 Oct 2015 WO
WO-2015156143 Oct 2015 WO
WO-2015164787 Oct 2015 WO
WO-2015179915 Dec 2015 WO
WO-2015179916 Dec 2015 WO
WO-2015179917 Dec 2015 WO
WO-2015181836 Dec 2015 WO
WO-2015187480 Dec 2015 WO
WO-2016001088 Jan 2016 WO
WO-2016006536 Jan 2016 WO
WO-2016019191 Feb 2016 WO
WO-2016075656 May 2016 WO
WO-2016108163 Jul 2016 WO
WO-2016118318 Jul 2016 WO
WO-2016120820 Aug 2016 WO
WO-2016136694 Sep 2016 WO
WO-2016141799 Sep 2016 WO
WO-2016151364 Sep 2016 WO
WO-2016160849 Oct 2016 WO
WO-2016175649 Nov 2016 WO
WO-2016178936 Nov 2016 WO
WO-2016190978 Dec 2016 WO
WO-2017001848 Jan 2017 WO
WO-2017004423 Jan 2017 WO
WO-2017027729 Feb 2017 WO
WO-2017035024 Mar 2017 WO
WO-2017053384 Mar 2017 WO
WO-2017062042 Apr 2017 WO
WO-2017142100 Aug 2017 WO
WO-2017165895 Sep 2017 WO
WO-2017192673 Nov 2017 WO
WO-2018007100 Jan 2018 WO
WO-2018013666 Jan 2018 WO
WO-2018033819 Feb 2018 WO
WO-2018044894 Mar 2018 WO
WO-2018064234 Apr 2018 WO
WO-2018067593 Apr 2018 WO
WO-2018082813 May 2018 WO
WO-2018091492 May 2018 WO
WO-2018096390 May 2018 WO
WO-2018145880 Aug 2018 WO
WO-2019014141 Jan 2019 WO
Non-Patent Literature Citations (4)
Entry
Cinterion., “Cinterion PHS8-P 3G Hspa+,” retrieved from http://www.cinterion.com/tl_files/cinterion/downloads/cinterion_datasheet_PHSS_web.pdf, 2012, 2 pages.
International Preliminary Report on Patentability for Application No. PCT/US2018/041313, mailed on Jan. 23, 2020, 9 pages.
International Search Report and Written Opinion for Application No. PCT/US2018/041313, mailed on Sep. 25, 2018, 10 pages.
U.S. Appl. No. 60/845,993, filed Sep. 19, 2006, 438 pages.
Related Publications (1)
Number Date Country
20230405213 A1 Dec 2023 US
Provisional Applications (1)
Number Date Country
62530480 Jul 2017 US
Continuations (1)
Number Date Country
Parent 16629190 US
Child 18209194 US